Justin E Bekelman1, Nandita Mitra2, Elizabeth A Handorf2, Robert G Uzzo2, Stephen A Hahn2, Daniel Polsky2, Katrina Armstrong2. 1. Justin E. Bekelman, Nandita Mitra, Stephen A. Hahn, and Daniel Polsky, University of Pennsylvania; Elizabeth A. Handorf and Robert G. Uzzo, Fox Chase Cancer Center, Philadelphia, PA; and Katrina Armstrong, Massachusetts General Hospital, Boston, MA. bekelman@uphs.upenn.edu. 2. Justin E. Bekelman, Nandita Mitra, Stephen A. Hahn, and Daniel Polsky, University of Pennsylvania; Elizabeth A. Handorf and Robert G. Uzzo, Fox Chase Cancer Center, Philadelphia, PA; and Katrina Armstrong, Massachusetts General Hospital, Boston, MA.
Abstract
PURPOSE: We examined whether the survival advantage of androgen-deprivation therapy with radiotherapy (ADT plus RT) relative to ADT alone for men with locally advanced prostate cancer reported in two randomized trials holds in real-world clinical practice and extended the evidence to patients poorly represented in the trials. METHODS: We conducted nonrandomized effectiveness studies of ADT plus RT versus ADT in three groups of patients diagnosed between 1995 and 2007 and observed through 2009 in the SEER-Medicare data set: (1) the randomized clinical trial (RCT) cohort, which included men age 65 to 75 years and was most consistent with participants in the randomized trials; (2) the elderly cohort, which included men age > 75 years with locally advanced prostate cancer; and (3) the screen-detected cohort, which included men age ≥ 65 years with screen-detected high-risk prostate cancer. We evaluated cause-specific and all-cause mortality using propensity score, instrumental variable (IV), and sensitivity analyses. RESULTS: In the RCT cohort, ADT plus RT was associated with reduced cause-specific and all-cause mortality relative to ADT alone (cause-specific propensity score-adjusted hazard ratio [HR], 0.43; 95% CI, 0.37 to 0.49; all-cause propensity score-adjusted HR, 0.63; 95% CI, 0.59 to 0.67). Effectiveness estimates for the RCT cohort were not significantly different from those from randomized trials (P > .1). In the elderly and screen-detected cohorts, ADT plus RT was also associated with reduced cause-specific and all-cause mortality. IV analyses produced estimates similar to those from propensity score-adjusted methods. CONCLUSION: Older men with locally advanced or screen-detected high-risk prostate cancer who receive ADT alone risk decrements in cause-specific and overall survival.
PURPOSE: We examined whether the survival advantage of androgen-deprivation therapy with radiotherapy (ADT plus RT) relative to ADT alone for men with locally advanced prostate cancer reported in two randomized trials holds in real-world clinical practice and extended the evidence to patients poorly represented in the trials. METHODS: We conducted nonrandomized effectiveness studies of ADT plus RT versus ADT in three groups of patients diagnosed between 1995 and 2007 and observed through 2009 in the SEER-Medicare data set: (1) the randomized clinical trial (RCT) cohort, which included men age 65 to 75 years and was most consistent with participants in the randomized trials; (2) the elderly cohort, which included men age > 75 years with locally advanced prostate cancer; and (3) the screen-detected cohort, which included men age ≥ 65 years with screen-detected high-risk prostate cancer. We evaluated cause-specific and all-cause mortality using propensity score, instrumental variable (IV), and sensitivity analyses. RESULTS: In the RCT cohort, ADT plus RT was associated with reduced cause-specific and all-cause mortality relative to ADT alone (cause-specific propensity score-adjusted hazard ratio [HR], 0.43; 95% CI, 0.37 to 0.49; all-cause propensity score-adjusted HR, 0.63; 95% CI, 0.59 to 0.67). Effectiveness estimates for the RCT cohort were not significantly different from those from randomized trials (P > .1). In the elderly and screen-detected cohorts, ADT plus RT was also associated with reduced cause-specific and all-cause mortality. IV analyses produced estimates similar to those from propensity score-adjusted methods. CONCLUSION: Older men with locally advanced or screen-detected high-risk prostate cancer who receive ADT alone risk decrements in cause-specific and overall survival.
Authors: Calpurnyia B Roberts; Peter C Albertsen; Yu-Hsuan Shao; Dirk F Moore; Amit R Mehta; Mark N Stein; Grace L Lu-Yao Journal: Am J Med Date: 2011-03 Impact factor: 4.965
Authors: Timothy J Daskivich; Kang-Hsien Fan; Tatsuki Koyama; Peter C Albertsen; Michael Goodman; Ann S Hamilton; Richard M Hoffman; Janet L Stanford; Antoinette M Stroup; Mark S Litwin; David F Penson Journal: Ann Intern Med Date: 2013-05-21 Impact factor: 25.391
Authors: Padraig Warde; Malcolm Mason; Keyue Ding; Peter Kirkbride; Michael Brundage; Richard Cowan; Mary Gospodarowicz; Karen Sanders; Edmund Kostashuk; Greg Swanson; Jim Barber; Andrea Hiltz; Mahesh K B Parmar; Jinka Sathya; John Anderson; Charles Hayter; John Hetherington; Matthew R Sydes; Wendy Parulekar Journal: Lancet Date: 2011-11-02 Impact factor: 79.321
Authors: Robert Steven Gerhard; Dattatraya Patil; Yuan Liu; Kenneth Ogan; Mehrdad Alemozaffar; Ashesh B Jani; Omer N Kucuk; Viraj A Master; Theresa W Gillespie; Christopher P Filson Journal: Urol Oncol Date: 2017-01-12 Impact factor: 3.498
Authors: J J Tosoian; R Alam; C Gergis; A Narang; N Radwan; S Robertson; T McNutt; A E Ross; D Y Song; T L DeWeese; P T Tran; P C Walsh Journal: Prostate Cancer Prostatic Dis Date: 2017-01-03 Impact factor: 5.554
Authors: J B Eifler; J Alvarez; T Koyama; R M Conwill; C R Ritch; K E Hoffman; M J Resnick; D F Penson; D A Barocas Journal: J Urol Date: 2016-10-27 Impact factor: 7.450